Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of EuNmCV-5 in Healthy Adults
NCT05739292Phase 1Completed
- Sponsor
- EuBiologics
- Start
- Feb 2023
- Primary completion
- May 2023
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EuNmCV-5 in meningococcal infection (2 arms), sponsored by EuBiologics. Primary endpoints: Occurrence of solicited adverse events at 7 days, Occurrence of unsolicited adverse events at 28 days and 1 more. Started Feb 2023; status: completed.
02
Drugs
EuNmCV-5
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT05739292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739292.